OVERVIEW
Although stimulant medications are the mainstay of treatment for attention deficit/hyperactivity disorder (ADHD), there are no guidelines on treatment for adults with ADHD. In addition, stimulant prescribing patterns and the risk for misuse and diversion of medications are growing concerns. This 30-minute symposium will explore patient-centered considerations, including psychiatric comorbidities and risk factors for misuse and diversion, in treatment selection for adults with ADHD.
GOAL STATEMENT
The goal of this activity is for learners to be better able to tailor treatment while effectively navigating risks of misuse and diversion of stimulant medications for adult patients with ADHD.
LEARNING OBJECTIVES
Upon completion of this activity, participants will: Have greater competence related to[list][item]Tailoring stimulant treatment selection for adult patients with ADHD[item]Identifying adult patients with ADHD who may benefit from modification of their stimulant treatment[/list]Demonstrate greater confidence in their ability to[list][item]Navigate risks of stimulant drug misuse and diversion in adult patients with ADHD[/list]
ACCREDITATION STATEMENT
[MEDSCAPE][JALOGO] In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
[bold]For Physicians[/bold] Medscape, LLC designates this live activity for a maximum of 0.50 [bold][italic]AMA PRA Category 1 Credits[/bold][/italic]™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Renaissance Orlando at SeaWorld
Room: Biscayne
6677 Sea Harbor Drive
Orlando, Florida, 32821
United States
THIS SYMPOSIUM IS NOT SPONSORED, ENDORSED OR ACCREDITED BY THE AMERICAN PROFESSIONAL SOCIETY FOR ADHD & RELATED DISORDERS.
Supported by an independent educational grant from [bold]Noven Pharmaceuticals[/bold].